BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysacc…
Biotechnology
US, San Rafael [HQ]
Ratios
15 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | 79.70 | 81.32 | 80.96 | 81.66 | 82.54 | 82.72 | 82.92 | 81.23 | 81.59 | 78.86 | 78.91 | 71.82 | 74.52 | 76.92 | 76.15 | |
| Profit Margin | -0.15 | 54.70 | -12.20 | -22.84 | -32.15 | -17.84 | -19.31 | -56.43 | -8.91 | -5.18 | -1.40 | 45.90 | -3.47 | 6.75 | 6.93 | |
| Operating Margin | 5.06 | 0.14 | -7.68 | -22.01 | -28.44 | -12.37 | -12.44 | -71.94 | -1.12 | -8.28 | -7.36 | -5.17 | -3.25 | 2.75 | 6.51 | |
|
EPS Growth
|
-101.58 | 40,712.25 | -124.12 | -97.92 | -34.74 | 28.13 | -16.30 | -255.14 | 82.37 | 34.33 | 70.46 | 3,753.85 | -107.37 | 317.14 | 17.11 | |
| EPS USD | -0.49 | 199.00 | -48.00 | -95.00 | -128.00 | -92.00 | -107.00 | -380.00 | -67.00 | -44.00 | -13.00 | 475.00 | -35.00 | 76.00 | 89.00 | |
| Return on Assets (ROA) | -0.05 | 16.30 | -4.13 | -7.14 | -7.84 | -5.38 | -4.61 | -15.66 | -2.53 | -1.74 | -0.51 | 14.60 | -1.07 | 2.22 | 2.45 | |
| Return on Equity (ROE) | -0.15 | 28.70 | -6.96 | -11.26 | -13.15 | -8.77 | -7.16 | -22.78 | -4.17 | -2.60 | -0.76 | 20.80 | -1.50 | 3.08 | 3.39 | |
| Return on Invested Capital (ROIC) | -1.73 | -0.45 | -3.73 | -7.81 | -7.81 | -4.56 | -4.01 | -17.66 | -1.20 | -1.76 | -0.79 | 37.63 | -0.95 | 0.96 | 2.32 | |
| Solvency | ||||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 54.20 | 35.89 | 26.72 | 21.74 | 29.15 | 26.42 | 17.76 | 16.98 | 25.35 | 18.76 | 18.08 | 18.59 | 18.15 | 17.15 | 16.02 | |
| Debt/Equity | 154.29 | 63.18 | 45.06 | 34.28 | 48.89 | 43.06 | 27.59 | 24.70 | 41.82 | 27.98 | 27.16 | 26.47 | 25.51 | 23.75 | 22.13 | |
| Debt/EBITDA | 1,511.07 | 3,586.20 | -945.29 | -182.43 | -73.06 | 157.89 | -92.33 | -142.86 | -804.00 | -335.60 | -1,846.31 | -7,281.83 | 1,024.03 | 224.74 | 144.57 | |
|
Debt/Capitalization
|
60.67 | 38.72 | 31.06 | 25.53 | 32.83 | 30.10 | 21.62 | 19.81 | 29.49 | 21.86 | 21.36 | 20.93 | 20.33 | 19.19 | 18.12 | |
| Long-Term Debt/Capitalization | 60.67 | 34.48 | 31.06 | 24.23 | 32.83 | 30.10 | 21.62 | 19.28 | 22.46 | 21.86 | 13.47 | 20.75 | 20.17 | 19.05 | 10.70 | |
| Interest Debt per Share USD | 5.10 | 4.50 | 3.18 | 2.96 | 4.83 | 4.77 | 4.38 | 4.35 | 6.98 | 4.94 | 4.87 | 6.17 | 6.04 | 5.99 | 5.93 | |
| Debt Growth | 602.68 | -24.05 | -7.73 | -0.03 | 88.26 | 0.37 | 0.66 | 3.16 | 71.90 | -29.29 | 2.13 | 26.77 | 0.37 | 0.37 | 4.70 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 598.47 | 601.43 | 499.13 | 436.22 | 620.62 | 604.75 | 244.61 | 323.64 | 270.31 | 392.98 | 208.27 | 475.53 | 421.32 | 467.23 | 251.15 | |
| Quick Ratio | 478.82 | 430.19 | 318.65 | 328.46 | 492.46 | 462.23 | 170.07 | 228.76 | 202.98 | 272.71 | 121.31 | 307.33 | 256.99 | 297.66 | 145.07 | |
| Cash Ratio | 213.90 | 105.05 | 49.16 | 105.92 | 310.35 | 371.38 | 89.13 | 92.95 | 73.24 | 94.41 | 46.91 | 131.80 | 108.79 | 123.03 | 64.16 | |
| Operating Cash Flow Ratio | 100 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Turnover | ||||||||||||||||
| Inventory Turnover | 83.79 | 64.07 | 64.57 | 71.36 | 58.88 | 65.06 | 55.95 | 59.03 | 50.82 | 59.39 | 52.84 | 75.05 | 60.58 | 54.10 | 52.12 | |
| Receivables Turnover | 441.47 | 434.61 | 420.99 | 459.10 | 465.52 | 519.85 | 539.46 | 518.79 | 502.61 | 435.22 | 451.52 | 414.96 | 494.45 | 454.36 | 381.76 | |
| Payables Turnover | - - | 1,418.18 | 686.52 | 62.44 | 100.46 | 55.05 | 38.73 | 56.58 | 60.16 | 72.10 | 63.00 | 273.87 | 243.79 | 209.17 | 182.90 | |
|
Asset Turnover
|
35.40 | 29.80 | 33.85 | 31.26 | 24.39 | 30.16 | 23.86 | 27.76 | 28.35 | 33.68 | 36.33 | 31.81 | 30.75 | 32.88 | 35.36 | |
| Fixed Turnover | 163.03 | 169.59 | 164.09 | 176.02 | 171.77 | 143.46 | 126.37 | 139.82 | 146.50 | 157.19 | 168.57 | 180.19 | 178.30 | 195.28 | 217.52 | |
| Coverage | ||||||||||||||||
| Interest Coverage | 116.59 | 5.27 | -405.92 | -1,442.79 | -1,493.32 | -253.51 | -289.46 | -2,034.05 | -34.42 | -282.90 | -534.77 | -328.43 | -391.30 | 360.34 | 909.13 | |
| Asset Coverage | 100 | 300 | 200 | 300 | 200 | 300 | 300 | 400 | 300 | 400 | 400 | 400 | 400 | 500 | 500 | |
| Cash Flow Coverage (CFGR) | 17.65 | 4.14 | 5.38 | 5.06 | -9.10 | -11.18 | -33.47 | -33.35 | -0.75 | 2.43 | 5.69 | 7.85 | 27.95 | 16.09 | 14.53 | |
| EBITDA Coverage | 100 | - - | -300 | -1,200 | -1,100 | -300 | -700 | -400 | -100 | -200 | - - | - - | 300 | 900 | 1,500 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | 100 | 100 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 100 | 100 | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -0.03 | 7.41 | -1.40 | -1.93 | -1.82 | -1.02 | -1.03 | -4.58 | -0.75 | -0.51 | -0.16 | 5.39 | -0.40 | 0.74 | 0.93 | |
|
Price/Earnings (P/E)
|
-386,495.39 | 1,348.90 | -7,160.18 | -5,174.89 | -5,495.26 | -9,826.09 | -9,758.04 | -2,181.84 | -13,288.95 | -19,526.68 | -63,475.96 | 1,856.46 | -25,210.63 | 13,544.11 | 10,803.16 | |
| Price/Earnings Growth (PEG) | 3,804.81 | -0.03 | 57.69 | -52.85 | -158.20 | 349.37 | -598.49 | -8.55 | 161.34 | 568.82 | 900.95 | -0.49 | 234.80 | -42.71 | 631.57 | |
|
Price/Book (P/B)
|
585.41 | 387.07 | 498.64 | 582.55 | 722.65 | 861.57 | 698.26 | 497.07 | 553.77 | 507.99 | 484.81 | 386.13 | 378.27 | 416.52 | 365.76 | |
| Price/Tangible Book (P/TB) | 585.41 | 387.07 | 498.64 | 582.55 | 722.65 | 861.57 | 698.26 | 497.07 | 553.77 | 507.99 | 484.81 | 386.13 | 378.27 | 416.52 | 365.76 | |
| Price/Sales (P/S) | 580.95 | 737.85 | 873.38 | 1,181.76 | 1,766.88 | 1,752.76 | 1,883.84 | 1,231.15 | 1,184.01 | 1,011.04 | 888.34 | 852.19 | 875.00 | 914.73 | 748.63 | |
|
Price/Cash Flow (P/CF)
|
2,149.84 | 14,810.06 | 20,555.40 | 33,604.03 | -16,250.90 | -17,900.58 | -7,562.04 | -6,035.10 | -177,613.97 | 74,607.80 | 31,365.77 | 18,572.84 | 5,304.78 | 10,899.92 | 11,372.01 | |
| Price/Free CF (P/FCF) | -91,159.86 | -9,038.89 | -2,845.55 | -21,946.94 | -7,767.89 | -6,842.91 | -3,730.84 | -3,654.86 | -7,478.58 | -12,118.40 | -13,146.80 | -30,399.78 | 8,717.76 | 43,219.82 | 35,066.13 | |
| Price/Operating CF (P/OCF) | 2,149.84 | 14,810.06 | 20,555.40 | 33,604.03 | -16,250.90 | -17,900.58 | -7,562.04 | -6,035.10 | -177,613.97 | 74,607.80 | 31,365.77 | 18,572.84 | 5,304.78 | 10,899.92 | 11,372.01 |